Candel Therapeutics, Inc.
CADLHealthcare|Biotechnology|US
$8.75
+0.71 (+8.83%)
DCF Value
$2.20
Tangible Book / Share
$1.70
Cash / Share
$2.72
About
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Stock Price
+77.1%(1Y)
1M
-9.4%
3M
-17.4%
6M
+4.8%
YTD
+54.9%
1Y
+72.6%
3Y
+775.0%
5Y
-23.8%
Pipeline Summary
14 total trials7
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
Recruiting: 2Completed: 7Active: 4Unknown: 1
Active Trials (6)
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
NCT07660094Non-squamous, Non-Small Cell Lung Cancer
Phase 3Recruiting
Enrollment: 500 participants
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
NCT04495153Non Small Cell Lung Cancer
Phase 2Active
Enrollment: 90 participants
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
NCT03152318Malignant Glioma of Brain
Phase 1Active
Enrollment: 62 participants
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000Prostate Cancer Patients Treated by Radiotherapy
Phase 2Recruiting
Enrollment: 45 participants
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
NCT01436968Prostate Cancer
Phase 3Active
Enrollment: 711 participants
Key Facts
Market Cap$669.5M
Employees55 (+45% YoY)
CEOPaul-Peter Tak
IPO DateJul 27, 2021
Beta-0.47
52-Week Range$4.35 – $14
Avg Volume1,193,849
ExchangeNASDAQ
Websitecandeltx.com
Ownership
Float78.7%
Shares Outstanding76.5M
Recent Insider Trades
Ostrovsky MariaAWARD
Nov 3, 2026315,000 shares @ $8.82
Ostrovsky MariaOTHER
Nov 3, 20260 shares
Loggia NicolettaAWARD
Sep 30, 2026380 shares @ $10.44
PAPA JOSEPH CAWARD
Sep 30, 20261,325 shares @ $10.44
Manning Paul BAWARD
Sep 30, 20262,189 shares @ $10.44
Peers
Recent News
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
Nov 6, 2026 · globenewswire.com
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026 · globenewswire.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026 · globenewswire.com
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
Oct 29, 2026 · globenewswire.com
Candel Therapeutics to Present at November Investor Conferences
Oct 27, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:00 AM